Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,029 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.
Hatta T, Hase T, Hara T, Kimura T, Kojima E, Abe T, Horio Y, Goto Y, Ozawa N, Yogo N, Shibata H, Shimokata T, Oguri T, Yamamoto M, Yanagisawa K, Ando M, Ando Y, Kondo M, Ishii M, Hasegawa Y. Hatta T, et al. Among authors: yamamoto m. Cancer Med. 2023 Aug;12(15):15955-15969. doi: 10.1002/cam4.6235. Epub 2023 Jun 23. Cancer Med. 2023. PMID: 37351560 Free PMC article.
Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Ando M, Saka H, Ando Y, Minami H, Kuzuya T, Yamamoto M, Watanabe A, Sakai S, Shimokata K, Hasegawa Y. Ando M, et al. Among authors: yamamoto m. Cancer Chemother Pharmacol. 2005 Jun;55(6):552-8. doi: 10.1007/s00280-004-0921-z. Epub 2005 Mar 15. Cancer Chemother Pharmacol. 2005. PMID: 15856233 Clinical Trial.
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Takahashi K, Saito H, Hasegawa Y, Ando M, Yamamoto M, Kojima E, Sugino Y, Kimura T, Nomura F, Ogasawara T, Shindoh J, Yoshida N, Suzuki R. Takahashi K, et al. Among authors: yamamoto m. Cancer Chemother Pharmacol. 2014 Oct;74(4):721-7. doi: 10.1007/s00280-014-2548-z. Epub 2014 Aug 3. Cancer Chemother Pharmacol. 2014. PMID: 25087097 Clinical Trial.
Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.
Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, Sugino Y, Yamamoto M, Ogasawara T, Kondo M, Imaizumi K, Hasegawa Y, Suzuki R, Shimokata K; Central Japan Lung Study Group. Nishiyama O, et al. Among authors: yamamoto m. Anticancer Drugs. 2011 Sep;22(8):811-6. doi: 10.1097/CAD.0b013e3283440231. Anticancer Drugs. 2011. PMID: 21317767 Clinical Trial.
Effects of Oral Morphine on Dyspnea in Patients with Cancer: Response Rate, Predictive Factors, and Clinically Meaningful Change (CJLSG1101).
Takahashi K, Kondo M, Ando M, Shiraki A, Nakashima H, Wakayama H, Kataoka K, Yamamoto M, Sugino Y, Nishikawa M, Imaizumi K, Kojima E, Sumida A, Takeyama Y, Saito H, Hasegawa Y. Takahashi K, et al. Among authors: yamamoto m. Oncologist. 2019 Jul;24(7):e583-e589. doi: 10.1634/theoncologist.2018-0468. Epub 2019 Jan 18. Oncologist. 2019. PMID: 30659079 Free PMC article.
Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y. Shindo Y, et al. Among authors: yamamoto m. Am J Respir Crit Care Med. 2013 Oct 15;188(8):985-95. doi: 10.1164/rccm.201301-0079OC. Am J Respir Crit Care Med. 2013. PMID: 23855620
Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y; Central Japan Lung Study Group. Shindo Y, et al. Among authors: yamamoto m. Lancet Infect Dis. 2015 Sep;15(9):1055-1065. doi: 10.1016/S1473-3099(15)00151-6. Epub 2015 Jul 2. Lancet Infect Dis. 2015. PMID: 26145194
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
Usami N, Yokoi K, Hasegawa Y, Taniguchi H, Shindo J, Yamamoto M, Suzuki R, Imaizumi K, Kondo M, Shimokata K; Central Japan Lung Study Group. Usami N, et al. Among authors: yamamoto m. Int J Clin Oncol. 2010 Dec;15(6):583-7. doi: 10.1007/s10147-010-0118-x. Epub 2010 Aug 17. Int J Clin Oncol. 2010. PMID: 20714770 Clinical Trial.
13,029 results
You have reached the last available page of results. Please see the User Guide for more information.